Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas

NCT02055924 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT02055924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02055924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 1
Overall status
Terminated
Start date
May 26, 2014
Completion date
October 9, 2018
Enrollment
85 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma